Humoral Factors Abrogating Cell-Mediated Immunity in the Tumor-Bearing Host

  • R. W. Baldwin
  • R. A. Robins
Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 72)

Abstract

The concept that tumor-specific immune responses may effectively control or even suppress tumor growth has developed from studies showing that immunity can be induced against many, although by no means all, experimentally induced animal tumors when transplanted into syngeneic hosts (Hellström and Hellström, 1969b; Sjögren, 1965; Baldwin, 1973). This was originally established in tests with animal tumors, either induced by chemical carcinogens or oncogenic viruses, or arising spontaneously, showing that syngeneic hosts preimmunized against tumor, e.g., by implantation of radiation-attenuated tumor cells, rejected a subsequent challenge graft of the same tumor. Following this, it was found in a number of instances that animals with a transplanted tumor developing at one site and which is beyond host control can, nevertheless, reject a concomitant challenge with the same tumor implanted at another site, providing that the challenge inoculum is not too great (Gershon et al., 1967; Vaage, 1971; Deckers et al., 1973; Chandradasa, 1973). This indicates that the tumor-bearing host has developed an effective immune response to tumor implanted at a second site and implies that either the response was too weak or developed too slowly to cause rejection of the primary tumor implant, or that, alternatively, host factor(s) may have modified the initial tumor-immune response.

Keywords

Migration Depression Chromium Lymphoma Recombination 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Baldwin, R. W.: Immunological aspects of chemical carcinogenesis. Advanc. Cancer Res. 18, 1–75 (1973)CrossRefGoogle Scholar
  2. Baldwin, R. W., Embleton, M. J.: Demonstration by colony inhibition methods of cellular and humoral immune reactions to tumour-specific antigens associated with aminoazo dye-induced rat hepatomas. Internat. J. Cancer 7, 17–25 (1971)CrossRefGoogle Scholar
  3. Baldwin, R. W., Embleton, M. J.: Neoantigens on spontaneous and carcinogen-induced rat tumours defined by in vitro lymphocytotoxicity assays. Internat. J. Cancer 13, 433–443 (1974)CrossRefGoogle Scholar
  4. Baldwin, R. W., Pimm, M. V.: BCG immunotherapy of a rat sarcoma. Brit. J. Cancer 28, 281–287 (1973)PubMedCrossRefGoogle Scholar
  5. Baldwin, R. W., Price, M. R.: Neoantigen expression in chemical carcinogenesis. In: Cancer: A Comprehensive Treatise, Vol. I. Becker, F. F. (ed.). New York: Plenum Press. In press 1975Google Scholar
  6. Baldwin, R. W., Vose, B. M.: Embryonic antigen expression on 2-acetyl-aminofluorene-induced and spontaneously arising rat tumours. Brit. J. Cancer 30, 209–214 (1974a)PubMedCrossRefGoogle Scholar
  7. Baldwin, R. W., Vose, B. M.: The expression of a phase-specific foetal antigen on rat embryo cells. Transplantation 18, 525–530 (1974b)PubMedCrossRefGoogle Scholar
  8. Baldwin, R. W., Bowen, J. G., Price, M. R.: Detection of circulating hepatoma D23 antigen and immune complexes in tumour-bearer serum. Brit. J. Cancer 28, 16–24 (1973 a)PubMedCrossRefGoogle Scholar
  9. Baldwin, R. W., Embleton, M. J., Moore, M.: Immunogenicity of rat hepatoma membrane fractions. Brit. J. Cancer 28, 389–399 (1973b)PubMedCrossRefGoogle Scholar
  10. Baldwin, R. W., Embleton, M. J., Price, M. R., Vose, B. M.: Embryonic antigen expression on experimental rat tumours. Transplant. Rev. 20, 77–99 (1974a)PubMedGoogle Scholar
  11. Baldwin, R. W., Embleton, M. J., Robins, R. A.: Cellular and humoral immunity to rat hepatoma-specific antigens correlated with tumour status. Internat. J. Cancer 11, 1–10 (1973c)CrossRefGoogle Scholar
  12. Baldwin, R. W., Glaves, D., Vose, B. M.: Embryonic antigen expression in chemically induced rat tumours. Internat. J. Cancer 10, 233–243 (1972a)CrossRefGoogle Scholar
  13. Baldwin, R. W., Glaves, D., Vose, B. M.: Differentiation between embryonic and tumour specific antigens on chemically-induced tumours. Brit. J. Cancer 29, 1–10 (1974b)PubMedCrossRefGoogle Scholar
  14. Baldwin, R. W., Harris, J. R., Price, M. R.: Fractionation of plasma membrane-associated tumour-specific antigen from an aminoazo dyeinduced rat hepatoma. Internat. J. Cancer 11, 385–397 (1973d)CrossRefGoogle Scholar
  15. Baldwin, R. W., Price, M. R., Robins, R. A.: Blocking of lymphocyte cytotoxicity for rat hepatoma cells by tumour-specific antigen-antibody complexes. Nature (Lond.) New Biol. 238, 185–187 (1972b)CrossRefGoogle Scholar
  16. Baldwin, R. W., Price, M. R., Robins, R. A.: Significance of serum factors modifying cellular immune responses to growing tumours. Brit. J. Cancer 28, Suppl. I, 37–47 (1973e)Google Scholar
  17. Baldwin, R. W., Price, M. R., Robins, R. A.: Inhibition of hepatomaimmune lymph node cell cytotoxicity by tumour-bearer serum and solubilized hepatoma antigen. Internat. J. Cancer 11, 527–535 (1973f)CrossRefGoogle Scholar
  18. Baldwin, R. W., Price, M. R., Vose, B. M.: Fetal antigen expression on chemically induced tumours and their relationship to α-fetoprotein. In: Proc. Internat. Conf. on Alpha-feto-protein. Masseyeff, R. (ed.), p. 181–189. Paris: INSERM, 1974cGoogle Scholar
  19. Bansal, S. C., Sjögren, H. O.: Unblocking serum activity in vitro in the polyoma system may correlate with antitumour effects of antiserum in vivo. Nature (Lond.) New Biol. 233, 76–77 (1971)Google Scholar
  20. Bansal, S. C., Sjögren, H. O.: Counteraction of the blocking of cellmediated tumor immunity by inoculation of unblocking sera and splenectomy: immunotherapeutic effects on primary polyoma tumors in rats. Internat. J. Cancer 9, 490–509 (1972)CrossRefGoogle Scholar
  21. Bansal, S. C., Sjögren, H. O.: Regression of polyoma tumor metastasis by combined unblocking and BCG treatment—correlation with induced alterations in tumor immunity status. Internat. J. Cancer 12, 179–193 (1973)CrossRefGoogle Scholar
  22. Bansal, S. C., Hargreaves, R., Sjögren, H. O.: Facilitation of polyoma tumor growth in rats by blocking sera and tumor eluate. Internat. J. Cancer 9, 97–108 (1972)CrossRefGoogle Scholar
  23. Basham, C., Currie, G. A.: Development of specific cell-dependent antibody during growth of a syngeneic rat sarcoma. Brit. J. Cancer 29, 189–198 (1974)PubMedCrossRefGoogle Scholar
  24. Belehradek, J., Barski, G., Thonier, M.: Evolution of cell mediated antitumor immunity in mice bearing a syngeneic chemically induced tumor. Influence of tumor growth, surgical removal and treatment with irradiated tumor cells. Internat. J. Cancer 9, 461–469 (1972)CrossRefGoogle Scholar
  25. Berke, G., Sullivan, K. A.: Temperature control of lymphocyte-mediated cytotoxicity in vitro. Transplant. Proc. 5, 421–423 (1973)PubMedGoogle Scholar
  26. Blair, P. B., Lane, M. A.: Serum factors in mammary neeplasia: enhancement and antagonism of spleen cell activity in vitro detected by different methods of serum factor assay. J. Immunol. 112, 439–443 (1974)PubMedGoogle Scholar
  27. Blair, P. B., Lane, M. A., Yagi, M. J.: Blocking of spleen cell activity against target mammary tumor cells by viral antigens. J. Immunol. 115, 190–194 (1975)PubMedGoogle Scholar
  28. Blasecki, J. W., Tevethia, S. S.: In vitro studies on the cellular immune response of tumor-bearing mice to SV40-transformed cells. J. Immunol. 114, 244–249 (1975)PubMedGoogle Scholar
  29. Bowen, J. G.: Tumour antigen in human cancer patients’ sera. Brit. J. Cancer. 32, 242 (1975)PubMedCrossRefGoogle Scholar
  30. Bowen, J. G., Baldwin, R. W.: Serum factor levels during pulmonary growth of transplanted rat hepatoma D23. To be published (1975)Google Scholar
  31. Bowen, J. G., Robins, R. A., Baldwin, R. W.: Serum factors modifying cell mediated immunity to rat hepatoma D23 correlated with tumour growth. Internat. J. Cancer 15, 640–650 (1975)CrossRefGoogle Scholar
  32. Bray, A. E., Holt, P. G., Roberts, L. M., Keast, D.: Early onset of serum blocking in a murine melanoma model. Internat. J. Cancer. In press (1975)Google Scholar
  33. Burk, M. W., Yu, S., Ristow, S. S., McKhann, C. F.: Refractoriness of lymph node cells from tumour-bearing animals. Internat. J. Cancer 15, 99–108 (1975)CrossRefGoogle Scholar
  34. Chandradasa, K. D.: The development of specific suppression of concomitant immunity in two syngeneic tumour-host systems. Internat. J. Cancer 11, 648–662 (1973)CrossRefGoogle Scholar
  35. Coggin, J. H., Anderson, N. G.: Cancer, differentiation and embryonic antigens: some central problems. Advanc. Cancer Res. 19, 106–165 (1974)Google Scholar
  36. Currie, G. A., Basham, C.: Serum-mediated inhibition of the immunological reactions of the patient to his own tumour: a possible role for circulating antigen. Brit. J. Cancer 26, 427–438 (1972)PubMedCrossRefGoogle Scholar
  37. Currie, G. A., McElwain, T. J.: Active immunotherapy as an adjunct to chemotherapy in the treatment of disseminated malignant melanoma: a pilot study. Brit. J. Cancer 31, 143–156 (1975)PubMedCrossRefGoogle Scholar
  38. Dauphinee, M. J., Taxal, M., Witz, I. P.: Generation of non-complement-fixing blocking factors by lysosomal extract treatment of cytotoxic anti-tumor antibodies. J. Immunol. 113, 948–953 (1974)PubMedGoogle Scholar
  39. Deckers, P. J., Davis, R. C., Parker, G. A., Mannick, J. A.: The effect of tumor size on concomitant tumor immunity. Cancer Res. 33, 33–39 (1973)PubMedGoogle Scholar
  40. Eilber, F. R., Morton, D. L.: Immunologic response to human sarcomas: relation of antitumor antibody to the clinical course. In: Progress in Immunology. Vol. I (ed. B. Amos), p. 951–957. New York: Academic Press 1971Google Scholar
  41. El Ridi, R., Bubeník, J.: Tumour-associated antigen in the serum of rats with large Rous sarcoma virus-induced tumours. Folia Biol. 19, 273–280 (1973)Google Scholar
  42. El Ridi, R., Bubeník, J.: Tumour associated transplantation antigen in sera of rats with large RSV-induced sarcomas. Int. J. Cancer 16, 83–90 (1975)PubMedCrossRefGoogle Scholar
  43. Faanes, R. B., Choi, Y. S., Good, R. A.: Escape from isoantiserum inhibition of lymphocyte-mediated cytotoxicity. J. Exp. Med. 137, 171–182 (1973)PubMedCrossRefGoogle Scholar
  44. Faanes, R. B., Choi, Y. S.: Interaction of isoantibody and cytotoxic lymphocytes with allogeneic tumor cells. J. Immunol. 113, 279–288 (1974)PubMedGoogle Scholar
  45. Forni, G., Comoglio, P. M.: Effect of solubilized membrane antigens and tumour bearer serum on tumour growth in syngeneic hosts. Brit. J. Cancer 30, 365–369 (1974)PubMedCrossRefGoogle Scholar
  46. Fujimoto, S., Chen, C. H., Sabbadini, E., Sehon, A. H.: Association of tumor and histocompatibility antigens in sera of lymphoma-bearing mice. J. Immunol. 111, 1093–1100 (1973)PubMedGoogle Scholar
  47. Fujimoto, S., Greene, M. I., Sehon, A. H.: Regulation of the immune response to tumor antigens. I. Immunosuppressor T cells in tumor bearing hosts. J. Immunol. In press (1975a)Google Scholar
  48. Fujimoto, S., Greene, M. I., Sehon, A. H.: Regulation of the immune response to tumor antigens. II. The nature of immunosuppressor T cells in tumor bearing hosts. J. Immunol. In press (1975b)Google Scholar
  49. Gershon, R. K., Carter, R. L., Kondo, K.: On concomitant immunity in tumour-bearing hamsters. Nature (Lond.) 213, 674–676 (1967)CrossRefGoogle Scholar
  50. Golub, S. H., Morton, D. L.: Sensitization of lymphocytes in vitro against human melanoma-associated antigens. Nature (Lond.) 251, 161–163 (1974)CrossRefGoogle Scholar
  51. Gorczynski, R. M., Knight, R. A.: Immunity to murine sarcoma virus induced tumors. Direct cellular cytolysis of 51Cr-labelled target cells in vitro and analysis of blocking factors which modulate cytotoxicity. Internat. J. Cancer. Submitted for publication (1975)Google Scholar
  52. Gorczynski, R. M., Kilburn, D. G., Knight, R. A., Norbury, C., Parker, D. C., Smith, J.B.: Nonspecific and specific immunosuppression in tumour-bearing mice by soluble immune complexes. Nature (Lond.) 254, 141–143 (1975)CrossRefGoogle Scholar
  53. Gupta, R. K., Morton, D. L.: Suggestive evidence for in vivo binding of specific antitumor antibodies in human melanomas. Cancer Res. 35, 58–62 (1975)PubMedGoogle Scholar
  54. Halliday, W. J.: Macrophage migration inhibition with mouse tumor antigens: properties of serum and peritoneal cells during tumor growth and after tumor loss. Cell. Immunol. 3, 113–122 (1972)PubMedCrossRefGoogle Scholar
  55. Halliday, W. J., Maluish, A., Miller, S.: Blocking and unblocking of cell-mediated anti-tumor immunity in mice as detected by the leucocyte adherence inhibition test. Cell. Immunol. 10, 467–475 (1974)PubMedCrossRefGoogle Scholar
  56. Hayami, M., Hellström, I., Hellström, K. E.: Serum effects on cell-mediated destruction of Rous sarcomas. Internat. J. Cancer 12, 667–688 (1973)CrossRefGoogle Scholar
  57. Hayami, M., Hellström, I., Hellström, K. E., Lannin, D. R.: Further studies on the ability of regressor sera to block cell-mediated destruction of Rous sarcomas. Int. J. Cancer 13, 43–53 (1974)PubMedCrossRefGoogle Scholar
  58. Hellström, I., Hellström, K. E.: Studies on cellular immunity and its serum mediated inhibition in Moloney-virus-induced mouse sarcomas. Int. J. Cancer 4, 587–600 (1969 a)PubMedCrossRefGoogle Scholar
  59. Hellström, I., Hellström, K. E.: Colony inhibition studies on blocking and non-blocking serum effects on cellular immunity to Moloney sarcomas. Int. J. Cancer 5, 195–201 (1970a)PubMedCrossRefGoogle Scholar
  60. Hellström, I., Hellström, K. E., Sjögren, H. O.: Serum-mediated inhibition of cellular immunity to methylcholanthrene-induced murine sarcomas. Cell. Immunol. 1, 18–30 (1970b)PubMedCrossRefGoogle Scholar
  61. Hellström, I., Hellström, K. E.: Cell-mediated immune reactions to tumor antigens with particular emphasis on immunity to human neoplasms. Cancer (Phila.) 34, 1461–1468 (1974a)CrossRefGoogle Scholar
  62. Hellström, I., Hellström, K.E.: Cytotoxic effect of lymphocytes from pregnant mice on cultivated tumor cells. I. Specificity, nature of effector cells and blocking by serum. Internat. J. Cancer 15, 1–16 (1975a)CrossRefGoogle Scholar
  63. Hellström, I., Hellström, K. E.: Cytotoxic effects of lymphocytes from pregnant mice on cultivated tumor cells. II. Blocking and unblocking of cytotoxicity. Internat. J. Cancer 15, 30–38 (1975b)CrossRefGoogle Scholar
  64. Hellström, I., Hellström, K. E., Pierce, G. E., Fefer, A.: Studies on immunity to autochthonous mouse tumors. Transplant. Proc. 1, 90–94 (1969)PubMedGoogle Scholar
  65. Hellström, I., Hellström, K. E., Sjögren, H. O., Warner, G. A.: Serum factors in tumor-free patients cancelling the blocking of cell mediated tumor immunity. Int. J. Cancer 8, 185–191 (1971)PubMedCrossRefGoogle Scholar
  66. Hellström, I., Warner, G. A., Hellström, K. E., Sjögren, H. O.: Sequential studies on cell-mediated tumor immunity and blocking serum activity in ten patients with malignant melanoma. Int. J. Cancer 11, 280–292 (1973)PubMedCrossRefGoogle Scholar
  67. Hellström, K. E.: Discussion. In: Schering Symposium on Immunopathology. Advanc. Biosciences 12, 551 (1974)Google Scholar
  68. Hellström, K. E., Hellström, I.: Cellular immunity against tumor antigens. Advanc. Cancer Res. 12, 167–223 (1969b)CrossRefGoogle Scholar
  69. Hellström, K. E., Hellström, I.: Immunological enhancement as studied by cell culture techniques. Ann. Rev. Microbiol. 24, 373–398 (1970b)CrossRefGoogle Scholar
  70. Hellström, K. E., Hellström, I.: Lymphocyte-mediated cytotoxicity and serum activity to tumor antigens. Advanc. Immunol. 18, 209–277 (1974b)CrossRefGoogle Scholar
  71. Henderson, W. R., Fukuyama, K., Epstein, W. L., Spitler, L. E.: Blocking of a cellular immune reaction to malignant melanoma by immunoglobulin from tumor-bearing animals. J. Reticuloend. Soc. 13, 155–160 (1973)Google Scholar
  72. Heppner, G. H.: In vitro studies on cell-mediated immunity following surgery in mice sensitized to syngeneic mammary tumors. Internat. J. Cancer 9, 119–125 (1972)CrossRefGoogle Scholar
  73. Howell, S. B., Dean, J. H., Law, L. W.: Defects in cell-mediated immunity during growth of syngeneic simian virus-induced tumor. Internat. J. Cancer 15, 152–169 (1975)CrossRefGoogle Scholar
  74. Jose, D. G., Seshadri, R.: Circulating immune complexes in human neuroblastoma. Direct assay and role in blocking specific cellular immunity. Internat. J. Cancer 13, 824–838 (1974)CrossRefGoogle Scholar
  75. Kirchner, H., Muchmore, A. V., Chused, T. M., Holden, H. T., Herberman, R. B.: Inhibition of proliferation of lymphoma cells and T lymphocytes by suppressor cells from spleens of tumor-bearing mice. J. Immunol. 114, 206–210 (1975)PubMedGoogle Scholar
  76. Knight, R. A., Gorczynski, R. M.: Cell mediated immunity to Moloney sarcoma virus in mice. I. Analysis of antigens responsible for lymphocyte stimulation in regressor mice. Internat. J. Cancer 15, 48–58 (1975)CrossRefGoogle Scholar
  77. Knight, R. A., Mitchison, N. A., Shellam, G. R.: Studies on a Gross-virusinduced lymphoma in the rat. II. The role of cell membrane-associated and serum p30 antigen in the antibody and cell-mediated response. Internat. J. Cancer 15, 417–428 (1975)CrossRefGoogle Scholar
  78. Kolb, J. P., Poupon, M. F., Lespinats, G.: Tumor-associated antigen (TAA) and anti-TAA antibodies in the serum of BALB/c mice with plasmacytomas. J. Nat. Cancer Inst. 52, 723–727 (1974)PubMedGoogle Scholar
  79. Lane, M. A., Roubinian, J., Slomich, M., Trefts, P., Blair, P. B.: Characterization of cytotoxic effector cells in the mouse mammary tumor system. J. Immunol. 114, 24–29 (1975)PubMedGoogle Scholar
  80. Laux, D., Lausch, R. N.: Reversal of tumor-mediated suppression of immune reactivity by in vitro incubation of spleen cells. J. Immunol. 112, 1900–1908 (1974)PubMedGoogle Scholar
  81. Le François, D., Youn, J. K., Belehradek, J., Barski, G.: Evolution of cell mediated immunity in mice bearing tumors produced by a mammary carcinoma cell line. Influence of tumor growth, surgical removal and treatment with irradiated tumor cells. J. Nat. Cancer Inst. 46, 981–987 (1971)PubMedGoogle Scholar
  82. Leonard, E. J.: Cell surface antigen movement: induction in hepatoma cells by antitumor antibody. J. Immunol. 110, 1167–1169 (1973)Google Scholar
  83. Martin-Chandon, M. R., Vanky, F., Carnaud, C., Klein, E.: In vitro ‘education’ on autologous human sarcoma generates non-specific killer cells. Internat. J. Cancer 15, 342–350 (1975)CrossRefGoogle Scholar
  84. Mikulska, Z. B., Smith, C, Alexander, P.: Evidence for an immunological reaction of the host directed against its own actively growing primary tumor. J. Nat. Cancer Inst. 36, 29–35 (1960)Google Scholar
  85. Mukojima, T., Gunvén, P., Klein, G.: Circulating antigen-antibody complex associated with Epstein-Barr virus in recurrent Burkitt’s lymphoma. J. Nat. Cancer Inst. 51, 1319–1322 (1973)PubMedGoogle Scholar
  86. Nelson, K., Pollack, S. B., Hellström, K. E.: Specific anti-tumor responses by cultured immune spleen cells. I. In vitro culture method and initial characterization of factors which block immune cell mediated cytotoxicity in vitro. Internat. J. Cancer 15, 806–814 (1975)CrossRefGoogle Scholar
  87. Nind, A. P. P., Matthews, N., Pihl, E. A. V., Rolland, J. M., Nairn, R. C.: Analysis of inhibition of lymphocyte cytotoxicity in human colon carcinoma. Brit. J. Cancer 31, 620–629(1975)PubMedCrossRefGoogle Scholar
  88. Noonan, P. F., Gardner, M. A. H., Clunie, G. J. A., Isbister, W. H., Halliday, W. J.: Control of tumor growth in mice by thoracic duct drainage: relationship to blocking factor in lymph. Internat. J. Cancer 13, 640–649 (1974)CrossRefGoogle Scholar
  89. Old, L. J., Boyse, E. A.: Immunology of experimental tumors. Ann. Rev. Med. 15, 167–186 (1964)PubMedCrossRefGoogle Scholar
  90. Paranjpe, M. S., Boone, C. W.: Kinetics of the anti-tumor delayed hypersensitivity response in mice with progressively growing tumors: stimulation followed by specific suppression. Internat. J. Cancer 13, 179–186 (1974)CrossRefGoogle Scholar
  91. Perlmann, P., Wigzell, H., Golstein, P., Lamon, E. W., Larsson, A., O’Toole, C., Perlmann, H., Svedmyr, E. A. J.: Cell mediated cytolysis in vitro: analysis of active lymphocyte subpopulations in different experimental systems. Ad vane. Biosciences 12, 71–85 (1974)Google Scholar
  92. Phillips, T. M., Lewis, M. G.: A method for elution of immunoglobulin from the surface of living cells. Rev. Europ. études Clin. Biol. 16, 1052–1053 (1971)Google Scholar
  93. Plata, F., Levy, J. P.: Blocking of syngeneic effector T cells by soluble tumour antigens. Nature (Lond.) 249, 271–274 (1974)CrossRefGoogle Scholar
  94. Pollack, S.: Specific ‘arming’ of normal lymph-node cells by sera from tumor-bearing mice. Internat. J. Cancer 11, 138–142 (1973)CrossRefGoogle Scholar
  95. Pollack, S., Heppner, G. H., Brawn, R. J., Nelson, K.: Specific killing of tumor cells in vitro in the presence of normal lymphoid cells and sera from hosts immune to the tumor antigen. Internat. J. Cancer 9, 316–323 (1972)CrossRefGoogle Scholar
  96. Poupon, M.-F., Lespinats, G., Kolb, I.P.: Blocking effect of the migration-inhibition reaction by sera from immunized syngeneic mice and by sera from plasmacytoma-bearing BALB/c mice. Detection of free, circulating tumor antigen. J. Nat. Cancer Inst. 52, 1127–114 (1974)PubMedGoogle Scholar
  97. Proctor, J. W., Rudenstam, C. M., Alexander, P.: A factor preventing development of lung metastases in rats with sarcomas. Nature (Lond.) 242, 29–31 (1973)CrossRefGoogle Scholar
  98. Ran, M., Witz, I. P.: Tumor-associated immunoglobulins. The elution of IgG2 from mouse tumors. Internat. J. Cancer 6, 361–372 (1970)CrossRefGoogle Scholar
  99. Ran, M., Witz, I.P.: Tumor-associated immunoglobulins: Enhancement of syngeneic tumors by IgG2-containing tumor eluates. Internat. J. Cancer 9, 242–247 (1972)CrossRefGoogle Scholar
  100. Rees, R. C., Price, M. R., Baldwin, R. W., Shah, L. P.: Inhibition of rat lymph node cell cytotoxicity by hepatoma-associated embryonic antigen. Nature (Lond.) 252, 751–753 (1974)CrossRefGoogle Scholar
  101. Rees, R. C., Price, M. R., Shah, L. P., Baldwin, R. W.: Detection of hepatoma-associated embryonic antigen in tumour-bearer serum. Transplantation 19, 424–429 (1975)PubMedCrossRefGoogle Scholar
  102. Robins, R. A.: Serum antibody responses to an ascitic variant of rat hepatoma D23. Brit. J. Cancer 32, 21–27 (1975)PubMedCrossRefGoogle Scholar
  103. Robins, R. A., Baldwin, R. W.: Tumour-specific antibody neutralization of factors in rat hepatoma-bearer serum which abrogate lymph node cell cytotoxicity. Internat. J. Cancer 14, 589–597 (1974)CrossRefGoogle Scholar
  104. Ruoslahti, E., Pihko, H., Seppälä, M.: Alpha-fetoprotein: immunochemical purification and chemical properties. Expression in normal state and in malignant and non-malignant liver disease. Transplant. Rev. 20, 38–60 (1974)PubMedGoogle Scholar
  105. Sharma, B., Terasaki, P. I.: In vitro immunization to cultured human tumor cells. Cancer Res. 34, 115–118 (1974)PubMedGoogle Scholar
  106. Shellam, G. R.: Studies on a Gross-virus-induced lymphoma in the rat. I. The cell-mediated immune response. Internat. J. Cancer 14, 65–82 (1974)CrossRefGoogle Scholar
  107. Shellam, G. R., Knight, R.A.: Antigenic inhibition of cell-mediated cytotoxicity against tumour cells. Nature (Lond.) 252, 330–332 (1974)CrossRefGoogle Scholar
  108. Sjögren, H. O.: Transplantation methods as a tool for detection of tumor-specific antigens. Progr. Exp. Tumor Res. 6, 289–322 (1965)PubMedGoogle Scholar
  109. Sjögren, H. O., Hellström, I., Bansal, S. C., Hellström, K. E.: Suggestive evidence that the “blocking antibodies” of tumor-bearing individuals may be antigen-antibody complexes. Proc. Nat. Acad. Sci. (Wash.) 68, 1372–1375 (1971)CrossRefGoogle Scholar
  110. Sjögren, H. O., Hellström, I., Bansal, S. C., Warner, G. A., Hellström, K. E.: Elution of blocking factors from human tumors capable of abrogating tumor-cell destruction by specifically immune lymphocytes. Internat. J. Cancer 9, 274–283 (1972)CrossRefGoogle Scholar
  111. Smith, H. G., Leonard, E. J.: Humoral immune responses to tumor-specific antigens in strain-2 guinea pigs. J. Nat. Cancer Inst. 53, 187–194 (1974)PubMedGoogle Scholar
  112. Sobczak, E., De Vaux St Cyr, Ch. H.: Study of the in vivo fixation of antibodies on tumors provoked in hamsters by injection of SV40-transformed cells (TSV5 C12). Internat. J. Cancer 8, 47–52 (1971)CrossRefGoogle Scholar
  113. Terry, W. D., Henkart, P. A., Coligan, J. E., Todd, C. W.: Carcinoembryonic antigen: characterization and clinical applications. Transplant. Rev. 20, 100–129 (1974)PubMedGoogle Scholar
  114. Thomson, D. M. P.: Soluble tumor-specific antigen and its relationship to tumor growth. Internat. J. Cancer 15, 1016–1029 (1975)CrossRefGoogle Scholar
  115. Thomson, D. M. P., Eccles, S., Alexander, P.: Antibodies and soluble tumour-specific antigens in blood and lymph of rats with chemically induced sarcomata. Brit. J. Cancer 28, 6–15 (1973a)PubMedCrossRefGoogle Scholar
  116. Thomson, D. M. P., Sellens, V., Eccles, S., Alexander, P.: Radioimmunoassy of tumour specific transplantation antigen of a chemically induced rat sarcoma: circulating soluble tumour antigen in tumour bearers. Brit. J. Cancer 28, 377–388 (1973b)PubMedCrossRefGoogle Scholar
  117. Thunold, S., Tönder, O., Larsen, O.: Immunoglobulins in eluates of malignant human tumors. Acta pat. microbiol. Scand. Suppl. 236, 97–100 (1973)Google Scholar
  118. Todd, R. F., Stulting, R. D., Berke, G.: Mechanism of blocking by hyperimmune serum of lymphocyte-mediated cytolysis of allogeneic tumor cells. Cancer Res. 33, 3203–3208 (1973)PubMedGoogle Scholar
  119. Todd, R. F., Stulting, R. D., Berke, G.: Mechanism of inhibition of lymphocyte-mediated cytolysis by blocking antiserum. In: Proc. 8th Leucocyte Culture Conf. (eds. K. Lindahl-Kiessling, D. Osoba), p. 379–384. New York: Academic Press 1974Google Scholar
  120. Vaage, J.: Concomitant immunity and specific depression of immunity by residual or reinjected syngeneic tumor tissue. Cancer Res. 31, 1655–1662 (1971)PubMedGoogle Scholar
  121. Vaage, J.: Specific desensitization of resistance against a syngeneic methylcholanthrene-induced sarcoma in C3Hf mice. Cancer Res. 32, 193–199 (1972)PubMedGoogle Scholar
  122. Vaage, J.: Influence of tumor antigen on maintenance versus depression of tumor specific immunity. Cancer Res. 33, 493–503 (1973)PubMedGoogle Scholar
  123. Vaage, J.: Circulating tumor antigens versus immune serum factors in depressing concomitant immunity. Cancer Res. 34, 2979–2983 (1974)PubMedGoogle Scholar
  124. Vanky, F., Stjernswärd, J., Klein, G., Steiner, L., Lindberg, L.: Tumor-associated specificity of serum-mediated inhibition of lymphocyte stimulation by autochthonous human tumors. J. Nat. Cancer Inst. 51, 25–32 (1974)Google Scholar
  125. Vasudevan, D. M., Brunner, K. T., Cerottini, J.-C.: Detection of cytotoxic T lymphocytes in the EL4 mouse leukemia system: increased activity of immune spleen and peritoneal cells following preincubation and cell fractionation procedures. Internat. J. Cancer 14, 301–313 (1974)CrossRefGoogle Scholar
  126. Whitney, R. B., Levy, J. G., Smith, A. G.: Influence of tumor size and surgical resection on cell-mediated immunity in mice. J. Nat. Cancer Inst. 53, 111–116 (1974)PubMedGoogle Scholar
  127. Witz, I. P.: The biological significance of tumor-bound immunoglobulins. Curr. Topics Microbiol. Immunol. 61, 151–171 (1973)Google Scholar
  128. Witz, I. P., Yagi, Y., Pressman, D.: IgG associated with microsomes from autochthonous hepatomas and normal liver of rats. Cancer Res. 27, 2295–2299 (1967)PubMedGoogle Scholar
  129. Youn, J. K., Le François, D., Barski, G.: In vitro studies on mechanism of the “eclipse” of cell-mediated immunity in mice bearing advanced tumors. J. Nat. Cancer Inst. 50, 921–926 (1973)PubMedGoogle Scholar
  130. Zöller, M., Price, M. R., Baldwin, R. W.: Cell-mediated cytotoxicity to chemically-induced rat tumours. Internat. J. Cancer 16, 593–606 (1975a)CrossRefGoogle Scholar
  131. Zöller, M., Price, M. R., Baldwin, R. W.: Inhibition of rat tumour-bearer and tumour-immune lymph node cell cytotoxicity by soluble tumour and embryo cell extracts. To be published (1975b)Google Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1975

Authors and Affiliations

  • R. W. Baldwin
    • 1
  • R. A. Robins
    • 1
  1. 1.Cancer Research Campaign LaboratoriesUniversity of NottinghamNottinghamEngland

Personalised recommendations